How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
当前的 LLM 应用开发正面临严重的“记忆碎片化”问题:我们有用于短期记忆的 KV Cache,有用于知识检索的 RAG,还有用于长期交互的 MemGPT ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果